Recursion, a clinical stage TechBio company decoding biology to industrialise drug discovery, today announced plans to open a new office in London’s vibrant King’s Cross neighbourhood.
Set to formally open in June 2024, the site will provide Recursion and Valence Labs, the company’s artificial intelligence research engine, access to world-class talent across Europe’s rapidly growing TechBio sector and embed Recursion in an nnovation ecosystem of leading technology and life science companies.
"As Recursion continues to influence the TechBio industry, it's critical we hire the best possible talent, much of which is located in Europe," said Chris Gibson, co-founder and CEO at Recursion.
"London stood out as an ideal location given its brilliant and interdisciplinary talent across the fields of technology, biology and chemistry. It’s also the epicentre for the rapidly growing TechBio sector in Europe, where leading technology and life science companies like Google and Merck both sit within walking distance of our new Recursion site.”
To support Recursion’s leadership in TechBio and entry into London, the company is excited to announce the addition of Michael Bronstein, DeepMind Professor of Artificial Intelligence at Oxford University, as a Scientific Advisor.
Professor Bronstein specialises in geometric deep learning, graph neural networks and protein design.
He joins AI luminary Professor Yoshua Bengio in supporting Recursion and Valence Labs in the development of AI models to support the industrialisation of drug discovery.
Prof. Michael Bronstein comments: “I have collaborated with Valence prior to their acquisition by Recursion, and I look forward to continuing to work with the team to advance this important work, especially as Recursion continues to grow in London.”
Recursion’s 6,700 sqft London office will be located at 3 Pancras Square, King’s Cross London. The building is part of a 67-acre redevelopment project in the heart of King’s Cross, with over 4.5m sqft of office space.
